In September 2015, when Galapagos NV lost its partnership with Abbvie Inc. for Janus kinase (JAK) 1 inhibitor filgotinib in rheumatoid arthritis (RA) – but kept intact their agreement for cystic fibrosis (CF) – the search for a new tie-up began right away, even as the spurning entity moved ahead with its own late-stage, oral JAK1 candidate in RA, ABT-494.